Calcium channel blockers not linked to breast cancer risk
Analysis of data on 50,757 women conflicts with previous research that suggested calcium channel blockers increase breast cancer risk
A study published in 2013 showed that women taking calcium channel blockers for at least ten years had a two-fold increased risk of breast cancer.
To explore this association prospectively, US researchers analysed data on 50,757 women from a study that has followed the sisters of women with breast cancer since 2003.
Over a median follow-up of 5.3 years, the risk of developing breast cancer was the same for long-term users of calcium channel blockers and women who did not take them. The rate of long-term calcium channel blocker use was identical (1.3%) among women who did and did not develop cancer.
Reporting in Breast Cancer Research (online, 5 July 2016), the team says their findings do not support previous reports suggesting an increased breast cancer risk, concerns over which could lead women to receive less effective hypertension treatment.
Citation: The Pharmaceutical Journal DOI: 10.1211/CP.2016.20201470
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com